Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street

Company Overview - Viking Therapeutics is a biotech company focused on developing therapies for chronic weight management, particularly in the context of obesity, which is a prevalent condition linked to various health issues [4]. - The company is currently a smaller player in the pharmaceutical industry but aims to carve out a niche in the rapidly growing weight-loss market [5]. Market Potential - The weight-loss market is expected to grow significantly over the next decade due to recent breakthroughs and the increasing prevalence of obesity [4]. - Viking Therapeutics' leading candidate, VK2735, is undergoing pivotal clinical trials, with results expected next year, which could influence the company's market position [5]. Clinical Development - VK2735 is being tested in two pivotal clinical trials: one involving adults with obesity and diabetes, and another with obese patients without diabetes, both measuring weight loss over a period of 78 weeks [5]. - The company is also developing an oral version of VK2735, which is anticipated to advance to phase 3 studies in the third quarter [5]. Valuation and Analyst Sentiment - Analysts consider Viking Therapeutics to be severely undervalued, with an average price target of $92.72, suggesting an upside of approximately 181% from current levels [2]. - Achieving the average price target will depend on the company posting strong phase 3 results for VK2735, with a need for competitive efficacy data and reasonable tolerability [6].